摘要
目的研究阿胶强骨口服液（donkey—hide glue reinforcing bone oral solution，DGRBOS）对SD大鼠血液25-羟基维生素D3（25-OH-VD3）、1，25-羟基维生素耽（1，25-（OH）2-VD3）和肝脏VDR基因表达的影响，探讨DGRBOS治疗骨质疏松的疗效机制：方法6月龄SD大鼠36只，随机分为A组（假手术组），B组（卵巢切除＋生理盐水组），C组（卵巢切除＋阿胶强骨口服液组），每组12只。6个月后取材检测。采用ELISA法对去势大鼠血清25-OH-VD3和1，25-（OH）2-VD3进行研究，用荧光定量PCR对肝脏VDR基因进行定量分析。结果C组（卵巢切除＋阿胶强骨口服液组）血液中25-羟基维他命D3浓度和1，25-羟基维他命D3浓度与B组（卵巢切除＋生理盐水组）比较明显增高，其中对25-羟基维他命D3浓度增高尤为明显，已接近A组（假手术组），P=0．002（P〈0．01），差异有明显的统计学意义。荧光定量PCR（FQ—PCR）结果B组与C组相比，P=0．004（P〈0．01），说明扩增效率的差异有明显的统计学意义。结论阿胶强骨口服液增加去势大鼠血液中25-OH-VD3、1，25-（OH）2-VD3的浓度，同时上调肝脏中VDR的表达水平，是阿胶强骨口服液治疗骨质疏松的机制之一。
Objective To investigate the effects of donkey-hide glue reinforcing bone oral solution （DGRBOS）on serum 25-OH-VD3,1,25-（OH）2-VD3 content and liver VDR gene expression in rats, and accordingly to probe into the efficacy of DGRBOS （donkey-hide glue reinforcing bone oral solution） on osteoporosis. Methods Female Sprague Dawley rats（ n = 36）, aged 6 months, were randomly divided into three groups. Group A were sham operated and given intragastric administration of normal sodium; group B were oophorectomized and given intragastric administration of normal sodium; group C were oophorectomized and given intragastric administration of DGRBOS. Animals were sacrificed after 6 months for determination of the 25-OH-VD3 and 1,25-（OH）2-VD3 concentration in serum by ELISA and quantitative analysis VDR gene expression by Fluorescence quantitative PCR （FQ-PCR）. Results We found group C had an obviously elevation of the 25-OH-VD3 and 1,25-（OH）2-VD3 concentration in serum compared with Group B （P = 0.002）, especially for 25-OH-VD3 , which showed similar results from Group A, and VDR gene expression also had a statistical significance between Group B and Group C （P=0.004）. Conclusion DGRBOS can increase serum 25-OH-VD3 and 1,25-（OH）2-VD3 concentration in ovariectomized rats, while increase in liver VDR expression, which is a possible mechanism for osteoporosis treatment with DGRBOS.
出处
《中国骨质疏松杂志》
CAS
CSCD
2009年第3期174-178,共5页
Chinese Journal of Osteoporosis
